Intercell receives €40 million option fee from Novartis
This article was originally published in Scrip
Intercell has received a €40 million option fee from Novartis as part of a deal signed in July 2007 to develop vaccines against infectious diseases. This brings total payments from the Swiss company to €270 million to date, following an equity investment of €150 million last September and a €80 million option and upfront licence fee in November. Werner Lanthaler, Intercell chief financial officer, expects the company to have around €200 million in cash by the end of the year.
You may also be interested in...
Laura Gonz�lez-Molero will be celebrating her first anniversary as President of Bayer HealthCare Pharmaceuticals, Latin America this month. With Bayer posting total sales of €1.05bnin Latin America in 2014, up 13% over 2013, Ms Gonz�lez-Molero should be pleased with a successful inaugural year. Resolute in her belief that innovation, "part of Bayer's DNA," will determine the company's long-term success in Latin America, rather than growth through acquisition, Ms Gonz�lez-Molero talks to Scrip about her personal ambitions for the company and the region.
A decade since its formation Anvisa, Brazil's medicines regulator, has shaken up the country's framework for ensuring drug quality. Yet the agency's approaches to drug pricing and registration have left some multinationals wanting, reports Sita Shah.
Elan is raising $1.5 billion in bonds to refinance its existing debt and for general corporate purposes, it says.